ResearchSOHO State of the Art Updates and Next Questions | Addressing the Transformative Questions in Aggressive B-Cell Lymphomas.
ResearchMinimal residual disease guided treatment approaches in non-Hodgkin lymphoma—Where we are and where we're headed.
ResearchA phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.
ResearchAn Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors.
ResearchAcute Transient Aminotransferase Elevation is Common With Intrathecal Methotrexate, but Liver Injury is Infrequent
ResearchCirculating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma: A Narrative Review
ResearchPhase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas
ResearchThe anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas
ResearchEnitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphoma
ResearchSpecificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas.
ResearchDiffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy
ResearchSpecificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas